Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.

Publication

Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.

Journal Paper/Review - Dec 1, 2023

Neubauer Moritz C, Nicolas Guillaume, Bauman Andreas, Fani Melpomeni, Nitzsche Egbert U, Afshar-Oromieh Ali, Forrer Flavio, Rentsch Cyrill A, Stenner-Liewen Frank, Templeton Arnoud J, Schäfer Niklaus G, Wild Damian, Chirindel Alin, all investigators on behalf of the SSNM Therapy Working Group

Citation

Neubauer M, Nicolas G, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, Forrer F, Rentsch C, Stenner-Liewen F, Templeton A, Schäfer N, Wild D, Chirindel A, all investigators on behalf of the SSNM Therapy Working Group. Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging 2023

Type

Journal Paper/Review (English)

Journal

Eur J Nucl Med Mol Imaging 2023

Publication Date

Dec 1, 2023

Issn Electronic

1619-7089

Brief description/objective

To assess early tumor response with quantitated SPECT/CT and to correlate it with clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with Lutetium-PSMA I&T therapy.